Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well
as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal
Colloidal Dispersion (NCD) administered in patients with recurrent glioblastoma multiforme
(GBM)